<p>Bright Minds Biosciences Inc.（纳斯达克代码：DRUG - 获取免费报告）在周五的午盘交易中创下了新的 52 周高点。该股最高交易价格为 79.30 美元，最后交易价格为 77.7170 美元，成交量为 138427 股。该股此前收盘价为 72.50 美元。</p>
<h2>分析师设定新的价格目标</h2>
<ul>
<li>生物科技处于边缘：2 只具有巨大潜力的股票</li>
</ul>
<p>几位研究分析师最近对 DRUG 股票发布了报告。HC Wainwright 在 9 月 15 日的研究报告中重申了对 Bright Minds Biosciences 的 “买入” 评级，并设定了 85.00 美元的目标价格。华尔街 Zen 在 10 月 3 日的研究报告中将 Bright Minds Biosciences 的评级从 “持有” 下调至 “卖出”。Chardan Capital 在 11 月 19 日的研究报告中将 Bright Minds Biosciences 的评级提升至 “强力买入”。BTIG Research 在 9 月 8 日的报告中开始覆盖 Bright Minds Biosciences，并为该公司设定了 “买入” 评级和 72.00 美元的目标价格。最后，Zacks Research 在周二的研究报告中将 Bright Minds Biosciences 的评级从 “强力买入” 下调至 “持有”。一位分析师给予该股 “强力买入” 评级，六位分析师给予 “买入” 评级，一位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “买入”，共识目标价格为 82.50 美元。</p>
<p><strong>查看我们关于 Bright Minds Biosciences 的最新报告</strong></p>
<h2>Bright Minds Biosciences 的价格表现</h2>
<ul>
<li>Bright Minds Biosciences 股票飙升近 1500%</li>
</ul>
<p>该公司的市值为 6.2677 亿美元，市盈率为-86.56，贝塔值为-6.22。该公司的 50 日简单移动平均线为 60.45 美元，200 日简单移动平均线为 43.53 美元。</p>
<h2>Bright Minds Biosciences 的机构交易</h2>
<p>几位大型投资者最近对 DRUG 的持仓进行了调整。Sio Capital Management LLC 在第二季度增持了 Bright Minds Biosciences 的股份，增幅为 0.9%。Sio Capital Management LLC 目前持有 512,338 股该公司的股票，价值为 13,377,000 美元，此前在上个季度增持了 4,776 股。Vivo Capital LLC 在第三季度增持了 Bright Minds Biosciences 的股份，增幅为 99.4%。Vivo Capital LLC 目前持有 501,617 股该公司的股票，价值为 30,428,000 美元，此前在上个季度增持了 250,045 股。Braidwell LP 在第三季度购买了 Bright Minds Biosciences 的新头寸，价值为 18,422,000 美元。Adage Capital Partners GP L.L.C.在第一季度增持了 Bright Minds Biosciences 的股份，增幅为 50.9%。Adage Capital Partners GP L.L.C.目前持有 200,000 股该公司的股票，价值为 7,214,000 美元，此前在上个季度增持了 67,500 股。最后，Millennium Management LLC 在第一季度增持了 Bright Minds Biosciences 的股份，增幅为 376.9%。Millennium Management LLC 目前持有 192,557 股该公司的股票，价值为 6,946,000 美元，此前在上个季度增持了 152,178 股。机构投资者和对冲基金持有该公司 40.52% 的股份。</p>
<h2>Bright Minds Biosciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>Bright Minds Biosciences Inc 是一家生物技术公司，开发治疗方案以改善美国重病患者的生活。其选择性 5-HT 受体激动剂的产品组合包括 5-HT2C、5-HT2A 和 5-HT2C/A，用于治疗癫痫、疼痛和神经精神疾病；以及 BMB-101，该药物已完成未公开癫痫病的第一阶段试验。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Bright Minds Biosciences</li>
<li>电话会议和个人投资者</li>
<li>Meta 的 AI 时刻？新 SAM 3 模型让华尔街变得乐观</li>
<li>便士股票适合你的投资组合吗？</li>
<li>Snowflake 股票：聪明投资者正在购买的下跌</li>
<li>如何做空纳斯达克：易于遵循的指南</li>
<li>Kraken Robotics 股票暴涨 1000%——现在华尔街正在关注</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Bright Minds Biosciences 吗？</h2>
<p>在你考虑 Bright Minds Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而 Bright Minds Biosciences 并不在名单上。</p>
<p>虽然 Bright Minds Biosciences 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票的详情</p>

DRUG

<p>Bright Minds Biosciences（纳斯达克代码：DRUG）达到了新的 52 周高点，交易价格为 79.30 美元。分析师的评级不一，HC Wainwright 设定的目标价为 85.00 美元，而其他分析师则下调了该股票的评级。该公司的市值为 6.2677 亿美元，机构投资者持有 40.52% 的股份。尽管获得了买入评级，但顶级分析师建议更好的投资选择</p>

<p>Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $79.30 and last traded at $77.7170, with a volume of 138427 shares changing hands. The stock had previously closed at $72.50.</p>
<div class="lb-trans"><p>Bright Minds Biosciences Inc.（纳斯达克代码：DRUG - 获取免费报告）在周五的午盘交易中创下了新的 52 周高点。该股最高交易价格为 79.30 美元，最后交易价格为 77.7170 美元，成交量为 138427 股。该股此前收盘价为 72.50 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><ul>
<li>Biotechs on the Brink: 2 Stocks With Huge Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技处于边缘：2 只具有巨大潜力的股票</li>
</ul>
</div><p>Several research analysts have recently issued reports on DRUG shares. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $85.00 price target on shares of Bright Minds Biosciences in a research note on Monday, September 15th. Wall Street Zen cut Bright Minds Biosciences from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Friday, October 3rd. Chardan Capital raised Bright Minds Biosciences to a &#34;strong-buy&#34; rating in a research note on Wednesday, November 19th. BTIG Research assumed coverage on Bright Minds Biosciences in a report on Monday, September 8th. They set a &#34;buy&#34; rating and a $72.00 target price for the company. Finally, Zacks Research cut shares of Bright Minds Biosciences from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of &#34;Buy&#34; and a consensus price target of $82.50.</p>
<div class="lb-trans"><p>几位研究分析师最近对 DRUG 股票发布了报告。HC Wainwright 在 9 月 15 日的研究报告中重申了对 Bright Minds Biosciences 的 “买入” 评级，并设定了 85.00 美元的目标价格。华尔街 Zen 在 10 月 3 日的研究报告中将 Bright Minds Biosciences 的评级从 “持有” 下调至 “卖出”。Chardan Capital 在 11 月 19 日的研究报告中将 Bright Minds Biosciences 的评级提升至 “强力买入”。BTIG Research 在 9 月 8 日的报告中开始覆盖 Bright Minds Biosciences，并为该公司设定了 “买入” 评级和 72.00 美元的目标价格。最后，Zacks Research 在周二的研究报告中将 Bright Minds Biosciences 的评级从 “强力买入” 下调至 “持有”。一位分析师给予该股 “强力买入” 评级，六位分析师给予 “买入” 评级，一位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “买入”，共识目标价格为 82.50 美元。</p>
</div><p><strong>Check Out Our Latest Report on Bright Minds Biosciences</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Bright Minds Biosciences 的最新报告</strong></p>
</div><h2>Bright Minds Biosciences Price Performance</h2>
<div class="lb-trans"><h2>Bright Minds Biosciences 的价格表现</h2>
</div><ul>
<li>Bright Minds Biosciences Stock Surges Almost 1,500%</li>
</ul>
<div class="lb-trans"><ul>
<li>Bright Minds Biosciences 股票飙升近 1500%</li>
</ul>
</div><p>The company has a market cap of $626.77 million, a price-to-earnings ratio of -86.56 and a beta of -6.22. The business has a 50 day simple moving average of $60.45 and a 200 day simple moving average of $43.53.</p>
<div class="lb-trans"><p>该公司的市值为 6.2677 亿美元，市盈率为-86.56，贝塔值为-6.22。该公司的 50 日简单移动平均线为 60.45 美元，200 日简单移动平均线为 43.53 美元。</p>
</div><h2>Institutional Trading of Bright Minds Biosciences</h2>
<div class="lb-trans"><h2>Bright Minds Biosciences 的机构交易</h2>
</div><p>Several large investors have recently made changes to their positions in DRUG. Sio Capital Management LLC boosted its stake in Bright Minds Biosciences by 0.9% in the 2nd quarter. Sio Capital Management LLC now owns 512,338 shares of the company's stock worth $13,377,000 after purchasing an additional 4,776 shares in the last quarter. Vivo Capital LLC increased its stake in shares of Bright Minds Biosciences by 99.4% in the 3rd quarter. Vivo Capital LLC now owns 501,617 shares of the company's stock worth $30,428,000 after purchasing an additional 250,045 shares in the last quarter. Braidwell LP bought a new position in Bright Minds Biosciences in the 3rd quarter worth $18,422,000. Adage Capital Partners GP L.L.C. lifted its stake in Bright Minds Biosciences by 50.9% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 200,000 shares of the company's stock worth $7,214,000 after purchasing an additional 67,500 shares in the last quarter. Finally, Millennium Management LLC increased its position in Bright Minds Biosciences by 376.9% in the first quarter. Millennium Management LLC now owns 192,557 shares of the company's stock worth $6,946,000 after purchasing an additional 152,178 shares during the last quarter. Institutional investors and hedge funds own 40.52% of the company's stock.</p>
<div class="lb-trans"><p>几位大型投资者最近对 DRUG 的持仓进行了调整。Sio Capital Management LLC 在第二季度增持了 Bright Minds Biosciences 的股份，增幅为 0.9%。Sio Capital Management LLC 目前持有 512,338 股该公司的股票，价值为 13,377,000 美元，此前在上个季度增持了 4,776 股。Vivo Capital LLC 在第三季度增持了 Bright Minds Biosciences 的股份，增幅为 99.4%。Vivo Capital LLC 目前持有 501,617 股该公司的股票，价值为 30,428,000 美元，此前在上个季度增持了 250,045 股。Braidwell LP 在第三季度购买了 Bright Minds Biosciences 的新头寸，价值为 18,422,000 美元。Adage Capital Partners GP L.L.C.在第一季度增持了 Bright Minds Biosciences 的股份，增幅为 50.9%。Adage Capital Partners GP L.L.C.目前持有 200,000 股该公司的股票，价值为 7,214,000 美元，此前在上个季度增持了 67,500 股。最后，Millennium Management LLC 在第一季度增持了 Bright Minds Biosciences 的股份，增幅为 376.9%。Millennium Management LLC 目前持有 192,557 股该公司的股票，价值为 6,946,000 美元，此前在上个季度增持了 152,178 股。机构投资者和对冲基金持有该公司 40.52% 的股份。</p>
</div><h2>Bright Minds Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Bright Minds Biosciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.</p>
<div class="lb-trans"><p>Bright Minds Biosciences Inc 是一家生物技术公司，开发治疗方案以改善美国重病患者的生活。其选择性 5-HT 受体激动剂的产品组合包括 5-HT2C、5-HT2A 和 5-HT2C/A，用于治疗癫痫、疼痛和神经精神疾病；以及 BMB-101，该药物已完成未公开癫痫病的第一阶段试验。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Bright Minds Biosciences</li>
<li>Conference Calls and Individual Investors</li>
<li>Meta’s AI Moment? New SAM 3 Model Has Wall Street Turning Bullish</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Snowflake Stock: The Dip That Smart Investors Are Buying Right Now</li>
<li>How to Short Nasdaq: An Easy-to-Follow Guide</li>
<li>Kraken Robotics Stock Exploded 1,000%—Now Wall Street Is Paying Attention</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Bright Minds Biosciences</li>
<li>电话会议和个人投资者</li>
<li>Meta 的 AI 时刻？新 SAM 3 模型让华尔街变得乐观</li>
<li>便士股票适合你的投资组合吗？</li>
<li>Snowflake 股票：聪明投资者正在购买的下跌</li>
<li>如何做空纳斯达克：易于遵循的指南</li>
<li>Kraken Robotics 股票暴涨 1000%——现在华尔街正在关注</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bright Minds Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Bright Minds Biosciences 吗？</h2>
</div><p>Before you consider Bright Minds Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Bright Minds Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bright Minds Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而 Bright Minds Biosciences 并不在名单上。</p>
</div><p>While Bright Minds Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Bright Minds Biosciences 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票的详情</p>
</div>

Bright Minds Biosciences（NASDAQ:DRUG）创下新的 1 年高点 - 以下是原因